EPS Group is a Full Service Provider of Optimized Pharmaceutical Solutions to Clients in the Healthcare Industry.
With the increasing the need of diversity and complexity of healthcare and intensifying competition in global markets, pharmaceutical companies and medical device manufacturers are required to adapt their operations to refocusing their resources on core businesses.
EPS Group provides a wide range of Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), and other related services for pharmaceutical and medical device development in Japan and Asia. By continuously building on our substantial wealth of experience, we have increased the efficiency of our operations and improved the quality of our services. The constant endeavor to continue these advances in all of our businesses and to provide solutions to our clients is captured in the words, “Ever Progressing System,” which is the origin of our company name and our business model.
Contact
EPS Building, 88 Jixian Street, Suzhou Industrial Park, Jiangsu Province, 215123 China
Tel: +86 512 62621166
Website: http://www.epschinagroup.com/
Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its…
VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Haematological oncologist Dr Raymond Liang, gives his take on the adoption and challenges of CAR-T therapy in Hong Kong, the necessity of collaboration with mainland China for patient referrals and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…
See our Cookie Privacy Policy Here
